

PROGRAMME

EUROPEAN CHARCOT FOUNDATION SYMPOSIUM 2011

Towards Personalized Treatment in Multiple Sclerosis

December 1, 2, and 3, 2011
Marbella, Spain

Thursday December 1, 2011

13.30	XVII European Charcot Foundation Lecture Towards Treatment of Persons with Multiple Sclerosis: on detour and access	Montalban, Barcelona
14.30 – 15.00	Discussion	
	SESSION I Rationale for personalized treatment in face of disease complexity	
15.00	Natural course, disease complexity and the differential diagnosis of inflammatory brain diseases	Edan, Rennes
15.20	Pathology: the mechanisms during early stages of the disease and later	Lassmann, Vienna
15.40	Genetics and environment. The natural course of Multiple Sclerosis and the personal history of the illness. Data from epidemiology	Ebers, Oxford
16.00	Personalized medicine: taking shared decision making seriously	Spreeuwenberg, Maastricht
16.20 – 16.50	Discussion	
16.50 – 17.20	<i>Coffee break</i>	
17.30 – 19.00	Integrated Satellite Symposium Merck Serono "Leveraging established therapies and modern data for individualized MS treatment" Chair: X. Montalban K. Selmaj	
17.30	Treatment tailoring and long term treatment benefits	Uitdehaag, Amsterdam
17.50	Individualized treatment from the first demyelinating event	Freedman, Ottawa
18.10	Impact of conventional and non-conventional MRI technology on patient management	Speaker invited
19.00 – 20.00	<i>Welcome Reception</i>	

Friday December 2, 2011

Session II

Tools for prognosis

08.30	MRI. Early activity, damage and progress of the disease	Fazekas, Graz
08.50	Future MRI Tools	Filippi, Milan
09.10	Prognostic possibilities of neurophysiology	Leocani, Milan
09.30	Biomarkers for damage, repair and side effects of treatment in MS prognosis	Giovannoni, London
09.50	Integrating the tools for an individualized prognosis	Fernandez, Malaga
10.10 – 10.30	Discussion	
10.30 – 11.00	<i>Coffee break</i>	

11.00 – 12.30 Integrated Satellite Symposium TEVA

"Guiding therapeutic decisions in MS: is it possible?"

Chair: J. Palace G. Comi

11.00	Defining the patient phenotype	Gold, Bochum
11.20	Targeting different aspects of disease pathology	Brück, Göttingen
11.40	Drug response markers to Glatiramer acetate	Centonze, Rome
12.00 – 12.30	Discussion	
12.30 – 14.00	<i>Lunch</i>	

Session III

Treatment heterogeneity, targets and risks

14.00	Viability of targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment	Hohlfeld, Munich
14.20	Combination therapies: the rationale of addition and synergy in personalized treatment	Comi, Milan
14.40	Risks in Multiple Sclerosis treatments on immune competence and neuroprotective autoimmunity in patients undergoing immunotherapy	Gold, Bochum

15.00	General risks of Multiple Sclerosis treatment	Du Pasquier, Lausanne
15.20 – 15.30	Discussion	
15.30 – 16.00	<i>Coffee break</i>	

Session IV
Treatment in practice

16.00	Decision on CIS treatment	Vass, Vienna
16.20	MRI and treatment decisions in daily practice	Brassat, Toulouse
16.40	Interferon-beta. To start and to stop	Derfuss, Basel
17.00	Personalized and participatory medicine in MS. How to translate pharmogenomics and genetics?	Miller, Haifa
17.20	Antibodies to interferon-beta and other treatments	Soelberg Soerensen, Copenhagen
17.40	Perspectives of ex-vivo testing for treatment responders: a key to personalized medicine in MS	Hemmer, Munich
18.00	Can biomarkers be selected to predict the course of CIS for every day practice	Sastre-Garriga, Barcelona
18.20 – 18.50	Discussion	
20.30	<i>Speakers' Dinner</i>	

Saturday December 3, 2011

Session V
Partnership

08.30	Partnership and consent in Multiple Sclerosis treatment	Palace, Oxford
08.50	Informed shared decision making and patient autonomy	Heesen, Hamburg
09.10	A patients perspective of partnership in the treatment of Multiple Sclerosis	Von Pückler, Frankfurt am Main
09.30 – 10.00	<i>Coffee break</i>	
10.00	How to implement partnership in every day clinical practice	Langdon, London

10.20 Measuring results of partnership treatment decisions. On new trial designs Uitdehaag, Amsterdam

Session VI

Personalized Treatment, Partnership and disease complexity

10.40 – Round Table Discussion
12.10 Guided by E. Havrdova and A. Boyko

12.10 – **European Charcot Foundation Young Investigators Awards**
12.40

12.40 Closure

13.00 – *Lunch*
14.00